20/20 Gene Systems

20/20 GeneSystems is a digital diagnostics company with a core mission to reduce cancer mortality rates in the United States and around the world through early detection. By harnessing the power of artificial intelligence and big data analytics, we aim to lower global cancer mortality rates through early detection. We have developed innovative tests centered around our proprietary algorithms to detect more than six common cancers. We believe in developing cutting-edge solutions by combining innovation with well-researched, established procedures. 20/20 GeneSystems has pioneered innovative biotests and cancer diagnostic tools that address significant unmet needs. 20/20’s digital diagnostics business develops and commercializes AI-driven cancer screening tests, providing better tools to improve the early detection of the most common cancers worldwide.Our urgent biotesting business includes our patented BioCheck, which is widely used by first responders. We now offer two testing products to detect antibodies against the virus that causes Covid-19, known as CoronaCheck.